Search

everythinglearnresearchcommunity

for

Search:↓

BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.

A woman with severe angioedema improved significantly after treatment with rituximab.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Mogamulizumab can cause hair loss and skin rashes.

Rosemary extract may boost the immune system, but more research on humans is needed to confirm this.

This method is effective for needle-free HIV-1 vaccination by activating immune responses in the skin.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Targeting SOX proteins may improve cancer treatment by restoring immune function.

IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.

Apremilast shows promise for several skin conditions but needs more research.

UV radiation may cause DNA changes in skin, certain UVB therapy helps psoriasis, a new gene mutation is linked to mild piebaldism, different immune cells affect psoriasis, a drug promotes hair growth, and some cancer drugs could treat skin barrier issues.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Inactive stem cells in hair follicles and muscles can avoid detection by the immune system.

Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.

Minoxidil helps hair regrowth in severe alopecia areata by changing immune cell behavior.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

High-dose steroid pulse therapy effectively regrows hair in severe multifocal alopecia areata.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.

Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Blocking certain immune signals can reduce skin damage from radiation therapy.